



## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

2. UPCOMING CONFERENCES: ASCO, BIO 2004 AND NEEDHAM BIOTECHNOLOGY CONFERENCE  
Press release of June 7, 2004: AETERNA ZENTARIS REPORTS  
ENCOURAGING RESULTS FROM PHASE I TRIAL OF PERIFOSINE IN  
COMBINATION WITH RADIOTHERAPY AT THE 2004 AMERICAN SOCIETY OF  
CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
- 

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.  
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881

AETERNA ZENTARIS

PRESS RELEASE  
For immediate release

AETERNA ZENTARIS TO PRESENT AT THREE UPCOMING CONFERENCES:  
ASCO, BIO 2004 AND NEEDHAM BIOTECHNOLOGY CONFERENCE

QUEBEC CITY, CANADA, JUNE 3, 2004 - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) announced today presentations at three upcoming conferences - ASCO, BIO 2004 and Needham Biotechnology Conference - in June 2004.

The first presentation will be at the American Society of Clinical Oncology Annual Meeting at the Ernest Memorial Convention Center in New Orleans, LA, on June 7, between 8:00 am and 12:00 noon CT. Marcel Verheij, M.D., of the Netherlands Cancer Institute, will present poster #N3-3064 "PHASE I STUDY OF COMBINED TREATMENT WITH THE ORAL ALKYL-LYSOPHOSPHOLIPID (ALP) PERIFOSINE AND RADIATION IN PATIENTS WITH ADVANCED SOLID TUMORS."

Also on June 7, Gilles Gagnon, President and Chief Executive Officer of Aeterna Zentaris, will provide a corporate update at BIO 2004 at 12:00 noon PT, at the Moscone Convention Center in San Francisco, CA.

Finally, on June 17, at 8:30 a.m. ET, Dr. Jurgen Engel, Executive Vice President, Global R&D and COO at Aeterna Zentaris, will provide a corporate update at the Third Annual Biotechnology Conference of Needham & Co., at the Palace Hotel in New York City, NY. A live webcast of the presentation will be available on the Company's website at [WWW.AETERNAZENTARIS.COM](http://WWW.AETERNAZENTARIS.COM) in the Investors section. A replay of the webcast will be available for a period of 90 days at the same address.

### ABOUT AETERNA ZENTARIS INC.

Aeterna Zentaris Inc. is a biopharmaceutical company focused in oncology and endocrine therapy. Its extensive portfolio, from drug discovery to marketed products, includes perifosine, an orally-active AKT inhibitor in several Phase II trials for multiple cancers, and cetrorelix, an LHRH antagonist already marketed for IN VITRO fertilization under the brand name Cetrotide(R), and also in advanced clinical development for the treatment of uterine myoma, endometriosis and benign prostatic hyperplasia (BPH).

Aeterna Zentaris owns 100% of Zentaris GmbH in Germany. It also owns 62% of Atrium Biotechnologies Inc., which develops, distributes and markets active

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

ingredients, specialty fine chemicals, cosmetic and nutritional products for the cosmetics, chemical, pharmaceutical and nutritional industries.

News releases and additional information about AETerna Zentaris are available on its new Web site WWW.AETERNAZENTARIS.COM.

### FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

-30-

### CONTACTS:

#### MEDIA RELATIONS

Paul Burroughs  
(418) 652-8525 ext. 406  
PAUL.BURROUGHS@AETERNAZENTARIS.COM

#### INVESTOR RELATIONS

Jacques Raymond  
(418) 652-8525 ext. 360  
JACQUES.RAYMOND@AETERNAZENTARIS.COM

#### U.S. INVESTOR RELATIONS

Lippert/Heilshorn & Associates  
Kim Golodetz  
(212) 838-3777  
kgolodetz@lhai.com

#### EUROPE

Matthias Seeber  
+49 69 42602 3425  
matthias.seeber@zentaris.de

AETerna Zentaris Inc. 1405 du Parc-Technologique Blvd.  
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881

AETerna Zentaris

PRESS RELEASE  
For immediate release

AETERNA ZENTARIS REPORTS ENCOURAGING RESULTS FROM PHASE I TRIAL  
OF PERIFOSINE IN COMBINATION WITH RADIOTHERAPY AT THE 2004  
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Data demonstrated acceptable safety/tolerability and preliminary evidence of antitumor activity, including multiple complete and partial responses, at all dosage levels.

NEW ORLEANS, JUNE 7, 2004 - AETerna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) announced today encouraging final results from recently completed Phase I trial evaluating perifosine, the Company's novel, first-in-class, oral AKT inhibitor, in combination with radiotherapy in patients with unresectable locally advanced tumors, in a poster session at the 2004 ASCO Annual Meeting, which takes place in New Orleans, LA. Marcel Verheij, M.D., of the Netherlands Cancer Institute, presented poster #N3-3064 entitled "Phase I Study of Combined Treatment with the Oral Alkyl-Lysophospholipid (ALP) Perifosine and Radiation in Patients with Advanced Solid Tumors."

A total of 21 radiotherapy-naive patients, of whom 17 had advanced non-small cell lung cancer (1 Stage IIIA, 15 Stage IIIB, 1 Stage IV) and 14 had become refractory to prior chemotherapy, received oral perifosine doses ranging from 50 mg to 200 mg/day concurrently with standard doses of radiotherapy. The trial data demonstrated the following: (i) acceptable safety and tolerability, with 150 mg/day established as the dose recommended for use in subsequent clinical trials; (ii) dose limiting toxicity (nausea/vomiting) at 200 mg/day; (iii) no bone marrow toxicity; and (iv) preliminary evidence of antitumor activity at all dosage levels, including complete or partial responses (complete disappearance and decreased tumor size, respectively), or stable disease, with a median follow-up for responders of 8 months (see Phase I trial data summary table at the end of the press release).

Importantly, in the cohort of 10 patients who were treated with 150 mg/day established as the dose recommended for use in subsequent clinical trials, there were 3 complete responses (2 non-small cell lung cancer (NSCLC) and 1 esophageal cancer), 3 partial responses (2 NSCLC and 1 prostate cancer), and 4 patients with stable disease. In addition, a patient with bladder cancer who received 50 mg/day perifosine had an unexpected finding, namely a long-lasting complete response.

These Phase I results support the ongoing clinical development of perifosine and will form the basis for subsequent placebo-controlled trials evaluating perifosine in combination with radiotherapy as a potential treatment for multiple types of cancer. Based on perifosine's pharmacokinetic profile (plasma concentration fluctuations), in future trials, perifosine will be administered 1 week prior to radiotherapy. AETerna Zentaris plans to initiate Phase II trials on perifosine in combination with radiotherapy through the ongoing collaboration with the Netherlands Cancer Institute of Amsterdam.

The ongoing clinical development of perifosine in North America includes nine open-label, single agent Phase II trials in six cancer types that are being conducted through collaboration with Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and the United States National Cancer Institute (NCI). AETerna Zentaris holds ex-North America rights to perifosine through Zentaris GmbH, which originally discovered and developed perifosine.

To date, five Phase I trials have been conducted on perifosine, including the trial highlighted at ASCO. In the four preceding trials, use of perifosine as a single agent in a total of 94 patients provided initial, encouraging evidence of antitumor activity. Namely, investigators observed two partial responses (>50% reduction) in patients with sarcoma and sixteen stable disease in patients with breast, prostate, pancreatic and other forms of cancer.

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

### ABOUT AETERNA ZENTARIS INC.

Aeterna Zentaris Inc. is a biopharmaceutical company focused in oncology and endocrine therapy. Its extensive portfolio, from drug discovery to marketed products, includes perifosine, an orally-active AKT inhibitor in several Phase II trials for multiple cancers, and cetrorelix, an LHRH antagonist already marketed for IN VITRO fertilization under the brand name Cetrotide(R), and also in advanced clinical development for the treatment of uterine myoma, endometriosis and benign prostatic hyperplasia (BPH).

Aeterna Zentaris owns 100% of Zentaris GmbH in Germany. It also owns 62% of Atrium Biotechnologies Inc., which develops, distributes and markets active ingredients, specialty fine chemicals, cosmetic and nutritional products for the cosmetics, chemical, pharmaceutical and nutritional industries.

News releases and additional information about Aeterna Zentaris are available on its new Web site [WWW.AETERNAZENTARIS.COM](http://WWW.AETERNAZENTARIS.COM).

### FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

-30-

### CONTACTS:

#### MEDIA RELATIONS

Paul Burroughs  
(418) 652-8525 ext. 406  
[PAUL.BURROUGHS@AETERNAZENTARIS.COM](mailto:PAUL.BURROUGHS@AETERNAZENTARIS.COM)

#### INVESTOR RELATIONS

Jacques Raymond  
(418) 652-8525 ext. 360  
[JACQUES.RAYMOND@AETERNAZENTARIS.COM](mailto:JACQUES.RAYMOND@AETERNAZENTARIS.COM)

#### U.S. INVESTOR RELATIONS

Lippert/Heilshorn & Associates  
Kim Golodetz  
(212) 838-3777  
[KGOLODETZ@LHAI.COM](mailto:KGOLODETZ@LHAI.COM)

#### EUROPE

Matthias Seeber  
+49 69 42602 3425  
[MATTHIAS.SEEBER@ZENTARIS.DE](mailto:MATTHIAS.SEEBER@ZENTARIS.DE)

SEE ATTACHED DOCUMENT

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

AETERNA ZENTARIS INC.

PHASE I TRIAL DATA SUMMARY, POSTER #N3-3064

-----

PERIFOSINE DOSE	NUMBER OF PATIENTS (N)	RESPONSE	TUMOR TYPE
50 mg/day	3	SD (N=2) CR (N=1)	Bladder
100 mg/day	3	SD (N=2) PR (N=1)	NSCLC
150 mg /day	10	SD (N=4) PR (N=3) CR (N=3)	1 Prostate; 2 NSCLC 2 NSCLC; 1 Esophageal
200 mg/day	5	SD (N=4) CR (N=1)	NSCLC

SD=stable disease; PR=partial response; CR=complete response

SIGNATURE

-----

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

DATE: JULY 20, 2004

-----

By: /S/MARIO PARADIS

-----  
Mario Paradis

Senior Director, Finance and Corporate Sec